Enzymatica AB (publ) is a company that embodies strong values and a clear corporate philosophy. The company focuses on developing and offering medical devices and healthcare products based on natural substances and enzymes. Enzymatica AB (publ) values innovation, research, and sustainability, striving to enhance human health with safe, effective, and environmentally friendly solutions. The company's commitment to excellence and quality is reflected in their products, which are designed to provide effective and gentle relief for various health conditions. Enzymatica AB (publ) is dedicated to improving the overall well-being of individuals and promoting a healthier future through their natural and scientifically-validated approach.

Enzymatica AB (publ) is primarily present in several countries and regions globally. The company has a strong presence in Sweden, its home country, where it is headquartered. Additionally, Enzymatica operates in other European countries including Norway, Denmark, Finland, and the United Kingdom. The company has expanded its business and distribution networks to reach markets in the Middle East, Asia, and Africa as well. With a focus on improving people's health, Enzymatica continues to explore potential opportunities for growth and expansion into new regions worldwide.

Some significant milestones achieved by Enzymatica AB (publ) include the launch of their flagship product, ColdZyme®, a cold spray that targets the cause of the common cold. The company has successfully expanded its geographical reach, securing partnerships and distribution agreements in several countries. Enzymatica has also received regulatory approvals and certifications, such as CE marking, allowing them to market their products across Europe. Additionally, the company has conducted successful clinical trials, highlighting the efficacy and safety of their products. Enzymatica AB (publ) continues to innovate and collaborate in the field of healthcare, aiming to improve the lives of individuals through their effective products.

Enzymatica AB (publ) is a renowned Swedish biotech company specializing in developing and marketing medical devices. Established in 2007, Enzymatica has achieved significant milestones throughout its history. The company's primary focus is on creating innovative solutions for infectious respiratory diseases, such as colds and flu. Enzymatica is widely recognized for its flagship product ColdZyme®, a mouth spray designed to reduce the risk of catching a cold. With a strong commitment to research and development, Enzymatica continues to expand its product portfolio and presence in global markets. The company's dedication to providing effective and safe healthcare products has earned it a reputable position in the industry.

The main competitors of Enzymatica AB (publ) in the market include pharmaceutical companies such as GlaxoSmithKline, Reckitt Benckiser, and Johnson & Johnson. These companies, like Enzymatica AB (publ), are involved in the development and commercialization of healthcare products, including nasal sprays and oral care solutions. They operate in the same industry and compete for market share with Enzymatica AB (publ) by offering similar products and solutions to consumers worldwide.

Enzymatica AB (publ) primarily operates in the pharmaceutical and healthcare industries.

Enzymatica AB (publ) operates with a business model focused on developing, producing, and marketizing innovative medical devices and healthcare products. The company specializes in enzymatic technology and develops products for ear care, oral care, and wound care. Enzymatica AB (publ) aims to address unmet medical needs through extensive research and development. With a strong emphasis on quality and scientific expertise, the company strives to bring effective and safe solutions to the healthcare market. Enzymatica AB (publ) continues to expand its product portfolio and enhance its presence in the global healthcare industry, creating value for both customers and shareholders.

Enzymatica AB (publ) P/E suhe on −7,62.

Enzymatica AB (publ) KUV on 6,05.

AlleAktien kvaliteediskoor ettevõttele Enzymatica AB (publ) on 6/10.

oodatud Enzymatica AB (publ) käive on 66,81 mln. SEK.

oodatud Enzymatica AB (publ) kasum on −53,05 mln. SEK.

Enzymatica AB (publ) is a Swedish company specializing in the development, production, and marketing of medical products for the treatment of respiratory infections and other diseases. The company's business model is based on a combination of high-quality products, innovative technologies, and strong marketing strategies. It has three divisions: Enzymatica medical, Enzymatica consumer, and Enzymatica research. Each division is specialized in a specific market and offers a range of products tailored to the needs of its respective target audience. Enzymatica medical develops medical products for the treatment of respiratory infections, sore throats, and other diseases. Enzymatica consumer manufactures products for health promotion and disease prevention. Enzymatica research focuses on the development of new products and technologies. The company has a strong marketing strategy, utilizing social media platforms, print and online advertising, and participation in relevant conferences and trade shows. Overall, Enzymatica AB (publ) offers innovative products and technologies for the treatment and prevention of respiratory and other diseases and continues to expand its presence in pharmacies and stores.

Enzymatica AB (publ) maksab dividendi 0 SEK, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Enzymatica AB (publ) jaoks arvutada või ettevõte ei maksa dividende välja.

Enzymatica AB (publ) ISIN on SE0003943620.

Enzymatica AB (publ) WKN on A1WZEV.

Enzymatica AB (publ) tähis on ENZY.ST.

Viimase 12 kuu jooksul maksis Enzymatica AB (publ) dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Enzymatica AB (publ) tõenäoliselt dividendi summas 0 SEK.

Enzymatica AB (publ) praegune dividenditootlus on .

Enzymatica AB (publ) maksab kvartaalset dividendi. See makstakse välja kuudel .

Enzymatica AB (publ) maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 SEK. See vastab dividenditootlusele 0 %.

Enzymatica AB (publ) on liigitatud sektorisse 'Tervis'.

Viimase Enzymatica AB (publ) dividendide saamiseks 4.7.2024 suuruses 0 SEK pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 4.7.2024.

Viimane dividendimakse toimus 4.7.2024.

Aastal 2023 maksis Enzymatica AB (publ) 0 SEK dividende.

Enzymatica AB (publ) dividendid makstakse välja SEK.